The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZTS | -21.43% | -6.21% | -1.27% | +423% |
| S&P | +14.5% | +93.32% | +14.09% | +343% |
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.
These two stocks will be at the top of my shortlist of stocks to add to in October.
Could Zoetis be the next big opportunity in the pet medicine market? Tune in as our experts break down the company's strengths and weaknesses.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.46B | 4.2% |
| Gross Profit | $1.78B | 7.2% |
| Gross Margin | 72.28% | 2.1% |
| Market Cap | $69.43B | -12.2% |
| Market Cap / Employee | $5.03M | 0.0% |
| Employees | 13.8K | -2.1% |
| Net Income | $718.00M | 15.1% |
| EBITDA | $1.11B | 7.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.44B | -8.8% |
| Accounts Receivable | $1.54B | 11.4% |
| Inventory | 2.4K | -0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.44B | -19.3% |
| Short Term Debt | $1.35B | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 18.24% | 1.4% |
| Return On Invested Capital | 19.40% | 1.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $308.00M | -16.8% |
| Operating Free Cash Flow | $486.00M | -3.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 36.73 | 29.81 | 29.57 | 26.83 | -20.96% |
| Price to Book | 17.85 | 14.06 | 15.48 | 14.94 | -4.59% |
| Price to Sales | 9.68 | 7.94 | 7.94 | 7.40 | -16.52% |
| Price to Tangible Book Value | 88.58 | 56.42 | 80.35 | 81.17 | 2.87% |
| Price to Free Cash Flow TTM | 57.39 | 48.61 | 50.21 | 50.31 | -13.26% |
| Enterprise Value to EBITDA | 89.96 | 88.18 | 81.65 | 67.29 | -17.46% |
| Free Cash Flow Yield | 1.7% | 2.1% | 2.0% | 2.0% | 15.29% |
| Return on Equity | 47.1% | 50.9% | 51.8% | 52.5% | 7.49% |
| Total Debt | $6.76B | $6.80B | $6.75B | $6.79B | 0.70% |
ZTS earnings call for the period ending December 31, 2024.
ZTS earnings call for the period ending September 30, 2024.
ZTS earnings call for the period ending June 30, 2024.
ZTS earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
